PI11340 2-Isopropyl-4-[(N-methylamino)methyl]thiazole hydrochloride (CAS No.: 908591-25-3)

2-Isopropyl-4-[(N-methylamino)methyl]thiazole hydrochloride (CAS No.: 908591-25-3) Description

2-Isopropyl-4-[(N-methylamino)methyl]thiazole hydrochloride (C8H15ClN2S) is a synthesised pharmaceutical intermediate featuring a thiazole core functionalised with an isopropyl substituent and an N-methylamino methyl side chain. The material is produced under strictly controlled conditions to ensure consistency in reactivity and purity. Its powdered form aids in accurate dosing and uniform mixing during chemical reaction processes in pharmaceutical synthesis.

2-Isopropyl-4-[(N-methylamino)methyl]thiazole hydrochloride (CAS No.: 908591-25-3) Applications

1.         Pharmaceutical Synthesis
   - Used as an intermediate in organic synthesis to achieve controlled heterocycle assembly by leveraging its targeted reactivity, facilitating efficient formation of complex drug molecules.

2.         Process Development
   - Applied as a standard compound in reaction optimisation studies to fine-tune catalytic conditions, ensuring reproducible outcomes and improved process scalability.

2-Isopropyl-4-[(N-methylamino)methyl]thiazole hydrochloride (CAS No.: 908591-25-3) Packing

The product is packaged in moisture-resistant, sealed containers to protect against ambient humidity and contamination. Each package is clearly labelled and designed for secure transport and storage. It is recommended to store the material in a cool, dry, and temperature-controlled environment. Custom packaging options are available to meet specific handling and shipping requirements, with additional anti-contamination measures upon request.

Additional Information

Pharmaceutical intermediates play a crucial role in the synthesis of active compounds by providing structurally defined building blocks. Their preparation requires precise control over composition and purity to ensure that subsequent chemical reactions proceed efficiently and predictably. Understanding the underlying chemistry and analytical validation methods enhances the ability to integrate these intermediates into larger synthetic protocols.

Advances in materials science and process engineering have enabled more effective control over reaction conditions during intermediate synthesis. This progress allows researchers to achieve reproducible results, supporting the development of innovative medicinal agents while adhering to strict regulatory and quality standards in pharmaceutical production.